GlassScriptPhysician profile
Lorena A Castillo
NPI 1194116616
$2,136.69
in general payments reported to CMS, 2019-2025
30 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $581 · 2023: $799 · 2024: $169 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.86 |
| Education | $146.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $251.57 | 2022-2023 | Adcetris, Tukysa |
| Incyte Corporation | $226.45 | 2022-2025 | Monjuvi, Zynyz |
| Pfizer INC. | $219.36 | 2023-2025 | |
| Celgene Corporation | $215.13 | 2022-2024 | Reblozyl, Opdualag |
| Lilly USA, LLC | $164.87 | 2021-2023 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $119.25 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.01 | 2022-2025 | Fruzaqla, Iclusig |
| Janssen Biotech, INC. | $75.44 | 2023-2024 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $74.18 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.69 | 2022-2023 | |
| Array Biopharma INC | $65.27 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Daiichi Sankyo INC. | $62.51 | 2022-2025 | Injectafer, Enhertu |
| Glaxosmithkline, LLC. | $55.83 | 2023 | Jemperli, Ojjaara, Zejula |
| Karyopharm Therapeutics INC. | $44.89 | 2023-2025 | Xpovio |
| Sobi, INC | $40.73 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $34.24 | 2025 | Brukinsa |
| G1 Therapeutics, INC. | $32.50 | 2022-2023 | Cosela |
| Deciphera Pharmaceuticals INC. | $32.29 | 2021 | |
| Genentech USA, INC. | $26.50 | 2023 | Phesgo, Rozlytrek, Tecentriq |
| Genzyme Corporation | $25.50 | 2024 | |
| Gilead Sciences, INC. | $24.52 | 2023 | Trodelvy |
| Merck Sharp & Dohme LLC | $23.81 | 2023 | Welireg, Keytruda, Lynparza |
| Exelixis INC. | $22.37 | 2023 | Cabometyx |
| Blueprint Medicines Corporation | $20.74 | 2022 | |
| Astellas Pharma US INC | $20.33 | 2023 | |
| Beigene USA, INC. | $20.30 | 2023 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $18.83 | 2025 | Myrisk |
| Alexion Pharmaceuticals, INC. | $18.04 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.84 | 2025 | Givlaari |
| Pharmacyclics LLC, An Abbvie Company | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorena Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.